Arvinas (ARVN) Total Liabilities (2017 - 2026)
Arvinas (ARVN) posted quarterly Total Liabilities of $260.7 million for Q1 2026, down 23.55% year-over-year from $341.0 million in Q1 2025, and down 8.2% quarter-over-quarter from $284.0 million in Q4 2025.
Arvinas (ARVN) Total Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Liabilities history runs 10 years deep, the most recent figure standing at $260.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 23.55% year-over-year to $260.7 million; the TTM figure through Mar 2026 stood at $260.7 million (down 23.55% YoY), while the FY2025 annual figure was $284.0 million, down 46.38% from the prior year.
- Total Liabilities for Q1 2026 stood at $260.7 million, down from $284.0 million in the prior quarter.
- The five-year high for Total Liabilities was $765.0 million in Q1 2022, with the low at $260.7 million in Q1 2026.
- The 5-year median for Total Liabilities is $602.9 million (2024), against an average of $547.5 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 1105.64% in 2022, then tumbled 55.84% in 2025.
- Arvinas' Total Liabilities stood at $703.9 million in 2022, then slipped by 8.42% to $644.6 million in 2023, then slipped by 17.83% to $529.7 million in 2024, then tumbled by 46.38% to $284.0 million in 2025, then declined by 8.2% to $260.7 million in 2026.
- Business Quant data shows ARVN's Total Liabilities at $260.7 million in Q1 2026, $284.0 million in Q4 2025, and $279.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 112.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.90 Mn |
| Mar 31, 2026 | 260.70 Mn |
| Dec 31, 2025 | 284.00 Mn |
| Sep 30, 2025 | 279.90 Mn |
| Jun 30, 2025 | 300.00 Mn |
| Mar 31, 2025 | 341.00 Mn |
| Dec 31, 2024 | 529.70 Mn |
| Sep 30, 2024 | 581.10 Mn |
| Jun 30, 2024 | 679.40 Mn |
| Mar 31, 2024 | 602.90 Mn |
| Dec 31, 2023 | 644.60 Mn |
| Sep 30, 2023 | 601.10 Mn |
| Jun 30, 2023 | 619.90 Mn |
| Mar 31, 2023 | 664.80 Mn |
| Dec 31, 2022 | 703.90 Mn |
| Sep 30, 2022 | 713.30 Mn |
| Jun 30, 2022 | 736.40 Mn |
| Mar 31, 2022 | 765.00 Mn |
| Dec 31, 2021 | 799.90 Mn |
| Sep 30, 2021 | 787.13 Mn |